You can hear the investor call (Roche doesn't issue Q3) . 7% growth, major growth in US. EU only 2%. Japan 3%. China great growth. NO specific talk on Erivedge sales (since it is not top 20 Roche drug). If we graph the trends, we will have at least 10% growth and I think few bulk payments. The Q3 report by CRIS should help push the share price to 5.0. Some clinical results will be expected before 2014.